Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06030375
Other study ID # KAN0004
Secondary ID 2019-004585-18
Status Completed
Phase Phase 1
First received
Last updated
Start date February 17, 2020
Est. completion date April 27, 2020

Study information

Verified date September 2023
Source Kancera AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study was planned to consist of 24 healthy subjects in 3 dosing cohorts receiving a continuous i.v. infusion of KAND567 or placebo for 6 h (6 subjects on active and 2 subjects on placebo per cohort), with the option of two additional cohorts of the same size and group composition.


Description:

The 3 planned dose levels of KAND567 were based on preliminary data from previous i.v. infusions and were chosen to obtain approximate Css levels of 0.5, 1.0 and 2.0 μM. The dose levels were 33.8 mg/6 h (cohort 1), 67 mg/6 h (cohort 2), or 134 mg/6 h (cohort 3). Each cohort of participants was planned to consist of 8 subjects (2 on placebo and 6 on active drug), i.e. a total of 24 subjects. A sentinel approach was used for all three cohorts, starting dosing with two subjects (one on active drug, one on placebo). If safe and tolerable, an additional two or three subjects will be administered. If safe and tolerable, the remaining three or four subjects of the cohort were dosed. There was an evaluation of safety and tolerability from the previous cohort prior to proceeding to the next cohort.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date April 27, 2020
Est. primary completion date April 27, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Provision of written informed consent prior to any study specific procedures - Body weight > 50 kg - Body Mass Index (BMI) = 19 and = 30 kg/m^2 at screening - Healthy male and female subjects aged = 18 and = 65 years at screening - Male subjects must agree to use an adequate method of contraception. Male subjects who are heterosexually active must use, with their partner, a condom AND one of the following methods of highly effective contraception from the time of IMP administration until 90 days after dosing of IMP. - oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable or implanted hormonal contraceptives - intrauterine device - intrauterine system (for example progestin-releasing coil) - vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate) - bilateral tubal occlusion or hysterectomy - Female subject must be of non-childbearing potential (defined as pre-menopausal females with a documented tubal ligation or hysterectomy or bilateral oophorectomy; or as post-menopausal females defined as 12 months' amenorrhoea [in questionable cases a blood sample with simultaneous follicle stimulating hormone 25-140 IE/L and estradiol < 200 pmol/L is confirmatory]) - Willingness and ability to comply with study procedures, visit schedules, study restrictions and requirements Exclusion Criteria: - Present or known history of clinically significant cardio- or cerebrovascular, pulmonary, renal, hepatic, neurological, mental, metabolic, endocrine, haematological, gastrointestinal disorder, significant respiratory disease, sleep apnoea, narcolepsy or any other major disorder that may interfere with the objectives of the study, as judged by the investigator - Any clinically significant abnormalities in physical examination, electrocardiogram (ECG; e.g. QTcF>450 ms), clinical chemistry, haematology or urinalysis results at screening, as judged by the investigator - Clinically significant abnormal blood pressure (treated or untreated), defined as systolic pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 90 mmHg at screening - Pulse rate < 45 bpm at screening - Clinically significant illness within the 5 days prior to the administration of the IMP - Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody or human immunodeficiency virus (HIV) - Known or suspected drug or alcohol abuse or positive screen for drugs of abuse test or positive alcohol breath test at screening visit or any time prior to randomisation - Smoking > 5 cigarettes per day, or inability to refrain from smoking or using other nicotine-containing products during the stay at the study centre. - Subject who has received any investigational drug within the last 3 months before administration of IMP - Plasma donation within one month of screening visit, or any blood donation/ blood loss > 450 mL during the 3 months prior to screening visit - Use of the herbal remedy St. John's Wort within two weeks prior to the first dose of the IMP (induces cytochrome P450-3A4) - Use of prescribed medication during the two weeks prior to the administration of the IMP (or longer if the prescribed medication has a half-life long enough to potentially expose the subject to any significant systemic exposure, as judged by the investigator) - Use of over-the-counter drugs (including herbals (St. John's Wort - see above), vitamins and minerals) during one week prior to the administration of the IMP or need for concomitant medication during the study. However, occasional paracetamol for pain relief is allowed (up to 3 g per 24 hours) - Female subjects: Positive pregnancy test at screening visit or at any time prior to randomisation - Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements - Subject has an eGFR < 80 mL/min/1.73m^2 at screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
KAND567
Continuous intravenous infusion for 6 hours
Other:
Placebo
Continuous intravenous infusion for 6 hours

Locations

Country Name City State
Finland Clinical Research Services Turku (CRST) Turku

Sponsors (1)

Lead Sponsor Collaborator
Kancera AB

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability after continuous infusion of KAND567, as measured by adverse events (AEs) Measured by the occurrence of AEs and serious adverse events (SAEs) From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
Primary Safety and tolerability after continuous infusion of KAND567, as measured by vital signs Measured by the occurrence of clinically abnormal vital signs From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
Primary Safety and tolerability after continuous infusion of KAND567, as measured by ECG Measured by the occurrence of clinically abnormal electrocardiography (ECG) From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
Primary Safety and tolerability after continuous infusion of KAND567, as measured by lab safety tests Measured by the occurrence of clinically abnormal lab test results (routine clinical chemistry, haematology, and urinalysis) From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
Primary Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by Css Measured by plasma drug concentration at steady state (Css) From the first IMP administration (Day 1) until Day 2
Primary Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by AUC Measured by the area under the plasma concentration-time curve (AUC) From the first IMP administration (Day 1) until Day 2
Primary Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by t1/2z Measured by terminal half-life (t1/2z) From the first IMP administration (Day 1) until Day 2
Primary Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by Vss Measured by the apparent volume of distribution at steady state (Vss) From the first IMP administration (Day 1) until Day 2
Primary Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by CL Measured by the systemic clearance (CL) From the first IMP administration (Day 1) until Day 2
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1